Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

liothyronine (Rx)Brand and Other Names:Cytomel, Triostat, more...Liothyronine T3, Thyroid Hormone

 
 
 

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

injectable solution

  • 10mcg/mL

tablet

  • 5mcg
  • 25mcg
  • 50mcg
more...

Hypothyroidism

Initial: 25 mcg PO qDay; may increase by 25 mcg q1-2Weeks; not to exceed 100 mcg/day

Maintenance: 25-75 mcg PO qDay

May use 10-12.5 mcg T3 in combo with T4 (decrease T4 dose by 50 mcg)

Nontoxic Goiter

Initial: 5 mcg PO qDay; may increase by 5-10 mcg q1-2Weeks (5 mcg in elderly)

When reach 25 mcg PO qDay, may increase by 12.5 mcg or 25 mcg q1-2Weeks

Maintenance: 75 mcg PO qDay

Myxedema

Initial: 5 mcg PO qDay; may increase by 5-10 mcg/day q1-2Weeks

When reach 25 mcg PO qDay, may increase by 5-25 mcg q1-2Weeks

Maintenance: 50-100 mcg PO qDay

Myxedema Coma

Initial: 25-50 mcg IV

Patients with CVD: 10-20 mcg IV

Doses of at least 65 mcg/day IV associated with lower mortality

Allow 4-12 hr between doses; not to exceed 12 hours

Dosage Forms & Strengths

injectable solution

  • 10mcg/mL

tablet

  • 5mcg
  • 25mcg
  • 50mcg
more...

Congenital Hypothyroidism

Initial: 5 mcg PO qDay; may increase by 5 mcg q3-4Days

Maintenance

  • <1 year: 20 mcg PO qDay
  • 1-3 years: 50 mcg PO qDay
  • >3 years: 25-75 mcg PO qDay

Nontoxic Goiter

Initial: 5 mcg PO qDay; may increase by 5-10 mcg q1-2Weeks

When reach 25 mcg PO qDay, may increase by 12.5 mcg or 25 mcg q1-2Weeks

Maintenance: 75 mcg PO qDay

5 mcg/day PO; may increase by 5 mcg/day q2Weeks

Next

Interactions

Interaction Checker

liothyronine and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            1-10%

            Tachycardia (3%)

            Hypotension (2%)

            Myocardial infarction (2%)

            Cardiopulmonary arrest (2%)

            <1%

            Congestive heart failure

            Hypertension

            Twitching

            Phlebitis

            Angina

            Fever

            Previous
            Next

            Warnings

            Black Box Warnings

            Thyroid hormones, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss

            In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction; larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines, such as those used for their anorectic effects.

            Contraindications

            Hypersensitivity to thyroid hormone

            Acute MI uncomplicated by hypothyroidism, thyrotoxicosis, untreated adrenal insufficiency

            Treatment of obesity or infertility

            Cautions

            Caution in angina, cardiovascular disease, hypopituitarism, DM

            May use judiciously in acute MI caused/complicated by hypothyroidism

            Perform periodic assessment of thyroid status when using as thyroid replacement

            Myxedematous patients are very sensitive to thyroid hormone; start at very low dose

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy category: A

            Lactation: Excreted into breast milk; use caution

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            A synthetic form of natural T3 hormone with same actions as natural product; thyroid hormone raises basal metabolic rate, increases utilization and mobilization of glycogen store, and promotes gluconeogenesis

            Absorption

            95% absorption

            Onset: 2-4 hr

            Duration: Several days (hypothyroidism)

            Peak plasma time: PO: 1-2 hr

            Max response: 2-3 days

            Distribution

            Protein bound: 99.7%, but not firmly

            Metabolism

            Hepatic, to deiodinated and conjugated metabolites

            Elimination

            Half-life: 2.5 days

            Excretion: Urine, feces

            Previous
            Next

            Administration

            IV Administration

            Administer q4hr; no more than 12 hr apart

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.